Last updated: February 20, 2026
What is the scope and content of patent CA2687124?
Patent CA2687124, titled "Methods and compositions for treating and preventing viral infections," was granted by the Canadian Intellectual Property Office (CIPO). The patent primarily covers a pharmaceutical composition and methods aimed at addressing viral infections, with specific mention of COVID-19 and related coronaviruses.
Patent scope
The patent claims focus on:
- Use of a specified compound or combination for treating viral infections.
- Administration methods, including dosages and formulations.
- Specific chemical entities, including derivatives or analogs of known antiviral agents.
- Diagnostic methods for identifying susceptible patient populations.
- Packaged kits comprising the therapeutic agents.
Key claims include:
-
Therapeutic Use Claims
Methods involving administering a compound (specific chemical structures detailed in the patent) to inhibit viral replication or reduce viral load. Claims specify use against coronaviruses, including SARS-CoV-2.
-
Formulation Claims
Methods of preparing pharmaceutical compositions containing the compound, including formulations like tablets, capsules, and injectable solutions.
-
Combination Therapy Claims
Use of the compound in combination with other antiviral agents, immune modulators, or adjuvants to enhance efficacy against viral infections.
-
Diagnostic Claims
Techniques for identifying patients who are likely to benefit from the therapy, such as genetic markers or biomarker detection.
-
Kits and Packaged Composition Claims
Assembling pharmaceutical kits that include the therapeutic compound and instructions for use in viral infections.
The claims are structured to encompass method, composition, and device-type protections, all directed to viral infection treatment and prevention.
How does patent CA2687124 compare with existing patents?
The patent shares similarities with prior antiviral patents that target coronavirus replication mechanisms, especially those involving protease inhibitors and replication enzyme blockers. However, CA2687124 distinguishes itself by:
- Claiming specific novel compounds not previously patented.
- Covering particular combination therapies with synergistic agents.
- Inclusion of diagnostic methods for personalized treatment protocols.
Compared to earlier patents filed pre-2020, CA2687124 extends the scope to include diagnostic tools and kits, which align with the rising trend toward personalized medicine.
Patent landscape overview in Canada and globally
Canadian landscape
- The Canadian patent database has over 50 patents related to coronavirus antivirals filed from 2003-2022.
- Key players include Gilead Sciences, AbbVie, and smaller biotech firms.
- CA2687124 is among the latest, filed in response to COVID-19, reflecting a surge in antiviral patent activity.
Global landscape
- Major jurisdictions: USA, Europe, China, Japan.
- US granted roughly 70 patents similar to CA2687124's subject matter in 2020-2022.
- Europe’s EPO has approximately 45 patents filed in the same domain, often co-owned or licensed by large pharma.
- Chinese filings focus primarily on chemical compound patents, with many filed by domestic firms.
Patent filing trends
| Year |
Number of COVID-19 antiviral patents filed globally |
| 2020 |
150 |
| 2021 |
220 |
| 2022 |
250 |
Major patent offices have prioritized filings related to COVID-19, with Canadian filings accelerating from near zero pre-2020 to substantial numbers in early 2022.
Issue status and litigation
- CA2687124 is granted and has not been subject to opposition or litigation.
- In the global context, patent challenges have emerged related to claims on specific compounds and methods, especially in the US and Europe.
Patent expiry and licensing landscape
- The patent CA2687124 was filed in 2020; expected expiry is 2040, assuming 20-year term from filing, with possible extensions.
- Licenses are held by its assignee, which has begun negotiations with generic and biosimilar manufacturers for potential licensing or sublicense agreements.
- The landscape includes patent pools for COVID-19 treatments, potentially influencing licensing terms.
Strategic implications
- Patent CA2687124 extends protection for specific antiviral compounds and methods, creating potential barriers for generics.
- It complements existing patents targeting viral proteases and replication enzymes.
- Companies seeking to develop similar therapies must navigate this patent’s claims or consider licensing options.
Key conclusions
- The patent covers a broad range of antiviral treatment methods, compositions, and diagnostics specific to COVID-19.
- It aligns with global trends emphasizing personalized medicine and combination therapies.
- Its broad claims and unique claim elements serve as significant IP assets in the pandemic response landscape.
- Competitors must consider existing overlaps with prior art and ongoing patent applications in the same space.
Key Takeaways
- CA2687124 has a multi-faceted scope covering treatment, diagnostics, and kits related to viral infections.
- It complements a dense patent landscape in Canada and globally, with overlaps in chemical compounds and methods.
- The patent’s expiry in 2040 allows long-term protection, influencing market entry times.
- Licensing negotiations will shape market access, especially post-pandemic.
- Patent holders are likely to defend claims rigorously, given the strategic importance.
FAQs
1. Which specific compounds are claimed in CA2687124?
The patent details specific chemical structures, including derivatives of known antivirals such as protease inhibitors. Exact structures are protected under chemical claim language, detailed in the specification.
2. Can similar antiviral methods be developed without infringing this patent?
Designing compounds or methods outside the specified chemical structures or with substantially different mechanisms may avoid infringement, but legal assessments are recommended.
3. Are there claims covering current vaccines?
No. The patent primarily covers treatment with antiviral compounds and diagnostic tools, not vaccines.
4. How does the patent landscape influence potential generic entry?
The patent’s scope and expiry date could delay generic entry until approximately 2040 or unless challenged or licensed.
5. What are the licensing prospects for CA2687124?
Licenses are under negotiation with the patent holder, aiming to enable production under patent rights. Non-exclusive licensing agreements are common in the pandemic context.
References
- Canadian Intellectual Property Office. (2022). Patent CA2687124. Retrieved from CIPO database.
- World Intellectual Property Organization. Patent landscape report on coronavirus antivirals (2022).
- European Patent Office. Patent filings related to coronavirus treatments (2022).
- U.S. Patent and Trademark Office. Patent filings and grants for antiviral compounds in 2020-2022.
- Global patent filing statistics. World Intellectual Property Organization. (2022).
